e-learning
resources
Munich 2014
Sunday, 07.09.2014
Novel evidence relating to respiratory treatment development
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Efficacy of Levodropropizine: 2 metanalysis in pediatric and adult population
A. Zanasi, F. De Blasio, L. Lanata, F. Saibene, G. Fontana (Bologna, Naples, Milan, Florence, Italy)
Source:
International Congress 2014 – Novel evidence relating to respiratory treatment development
Session:
Novel evidence relating to respiratory treatment development
Session type:
Thematic Poster Session
Number:
948
Disease area:
Paediatric lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Zanasi, F. De Blasio, L. Lanata, F. Saibene, G. Fontana (Bologna, Naples, Milan, Florence, Italy). Efficacy of Levodropropizine: 2 metanalysis in pediatric and adult population. Eur Respir J 2014; 44: Suppl. 58, 948
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Late Breaking Abstract - Efficacy of Breathox® device inhalation on acute symptoms associated with COVID-19 (BREATH study)
Related content which might interest you:
As-needed formoterol (F) in asthma: An analysis of the East-Asian subgroup of the RELIEF study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Experience with omalizumab in patients with moderate and severe asthma
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Abediterol: Efficacy, safety and tolerability of the novel LABA in patients with persistent asthma
Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases
Year: 2014
LATE-BREAKING ABSTRACT: Oral corticosteroid-sparing effect of mepolizumab in severe eosinophilic asthma: the SIRIUS study
Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment
Year: 2014
Characteristics of the adult corticosteroid-dependent severe asthma in UBIOPRED consortium
Source: International Congress 2014 – Novel targets and drugs for asthma and COPD
Year: 2014
Efficacy and safety of indacaterol acetate on ICS background therapy in asthma
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Effect of cromolyn inhaler on resistant neutrophilic cough variant of asthma, A phase two clinical trial
Source: International Congress 2014 – Rationale behind respiratory drug development
Year: 2014
Inflammation in COPD patients before and after roflumilast treatment
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Frequency of COPD exacerbations in the real-life out-patient DACCORD cohort
Source: International Congress 2014 – Rationale behind respiratory drug development
Year: 2014
Efficacy of omalizumab in Polish real-world patients
Source: International Congress 2016 – Asthma management
Year: 2016
Safety of tiotropium in renally impaired patients
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
What are common COPD symptoms in a real-life setting? The German DACCORD registry
Source: International Congress 2014 – COPD markers
Year: 2014
Pharmacokinetics of tiotropium in asthma patients from three paediatric clinical trials
Source: International Congress 2016 – Paediatric asthma: lessons learned from studies with large sample sizes and multi-centre drug studies
Year: 2016
Metered-dose inhaler albuterol: Evaluation of efficacy and safety of increasing doses in children with acute wheezing
Source: International Congress 2014 – Paediatric asthma: lung function testing and more
Year: 2014
Clinical effectiveness of anti-IgE therapy in allergic severe asthma
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Efficacy and safety of fluticasone propionate/formoterol in paediatric patients with asthma
Source: International Congress 2014 – Paediatric asthma: pharmacological and non-pharmacological management
Year: 2014
LATE-BREAKING ABSTRACT: Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study
Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment
Year: 2014
Once-daily tiotropium Respimat add-on to at least ICS in adult patients with symptomatic asthma: Pooled safety analysis
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Comparative effectiveness of paediatric asthma step-up options: Increasing ICS dose vs adding separate LABA
Source: International Congress 2014 – Paediatric asthma: what is new for the clinician?
Year: 2014
Adrenal suppression in paediatric asthmatic patients
Source: Annual Congress 2013 –Uncontrolled and severe asthma in children
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept